Incyclix Bio is testing a new drug called INX-315 for patients with advanced cancer. This drug is a small molecule inhibitor, which means it can block certain proteins involved in cancer growth. The study is divided into three parts:
- Part A: Tests different doses of INX-315 to find the safest dose. Up to 60 patients with advanced cancer will participate.
- Part B: Focuses on patients with advanced ovarian cancer. This part will test at least two doses selected from Part A.
- Part C: Involves patients with a specific type of breast cancer and tests INX-315 with other treatments.
To join, patients must have advanced cancer that has worsened after standard treatments. They should have good organ function and no history of certain diseases or conditions. They should not have taken similar treatments before.
- Study involves multiple visits over an extended period.
- Potential benefits include access to a new cancer treatment.
- Risks include side effects and the possibility of not responding to the treatment.
How understandable was the trial content above?
Hard to understand
Easy to understand